- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04326218
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)
National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on:
- incidence of MN
- prevalence of anti-PLA2R1 and anti-THSD7A
- clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome)
- environmental risk factors for the onset of MN
- HLA markers
- patient care status in France
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Membranous nephropathy is a rare auto-immune disease, yet a major cause of nephrotic syndrome in adults. It is characterised by the deposition of antigen-antibody complexes on the glomerular basement membrane, leading to a decreased filtration rate and eventually kidney failure. About one third of cases have a favourable outcome without any treatment, another third requires a long term symptomatic treatment to manage their symptoms, and the last third of patients advances to end stage renal failure, requiring dialysis and kidney graft. MN can be associated with cancer, infections, other auto-immune diseases and with certain drugs (secondary MN), but most often it is idiopathic. In the latter form two antigens have been identified, PLA2R1 and THSD7A, with corresponding auto-antibodies in 70% and 2% of MN patients, respectively. GWAS studies identified several alleles associated with a higher risk of developing MN, however, since these are common variants they cannot explain the onset of MN in the vast majority of cases. Since MN is a rare disease, the number of new cases per each center is low, and nation-wide studies are needed to correctly evaluate its incidence and risk factors for the onset of MN, as well as validate previously published findings in monocentric studies on the prognostic value of PLA2R1 epitope spreading (immunisation against multiple domains of PLA2R1).
This study aims to establish a French national cohort of all cases of MN in a one year period in France. The inclusion will last one year with one additional year of follow-up, for a total of 2 years. In the first year, nephrologists of each associate centers in France will propose the study to each of their patients diagnosed with MN. In addition, clinical information will be collected, as well as a survey on patients' lifestyle habits. Serum samples will be sent for centralised analyses in Nice.
This study will help to clarify the results from single center studies, such as the prognostic value of epitope spreading. The information acquired on environmental risk factors will help us understand the pathophysiological mechanisms leading to the onset of MN et, by association, to other auto-immune diseases. With this knowledge, measures could be put in place to protect the population at risk.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Barbara SEITZ-POLSKI, MD
- Phone Number: +33 4 92 03 55 02
- Email: seitz-polski.b@chu-nice.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or more
- Biopsy on a native kidney consistent with MN and/or positivity for serum anti-PLA2R1 and/or anti-THSD7A antibodies
- Signed informed consent
Exclusion Criteria:
- Diagnosis error based on the kidney biopsy staining or on serology analyses for the positivity for anti-PLA2R1 and/or anti-THSD7A
- Patients unable to give an informed consent
- Patients withdrawing an informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort
All patients included will have to be taken blood samples
|
Serum samples will be sent for centralised analyses in Nice. On these samples, different analysis will be performed :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the incidence of Membranous Nephropathy (MN) and its evolution
Time Frame: one year after inclusion
|
as either complete remission (UPCR < 0.3 g/g, serum albumin > 35 g/L, eGFR > 60 ml/min/1.73
m²) or partial remission (UPCR < 3.5 g/g and reduction of at least 50% from baseline, < 20% increase of serum creatinin from baseline) or persistent nephrotic syndrome (UPCR > 3.5 g/g, serum albumin < 30 g/L)
|
one year after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of incidence of primary and secondary forms of MN
Time Frame: 24 months
|
24 months
|
|
Identification of environmental factors associated with the onset of MN
Time Frame: 24 months
|
Thanks to a specific questionnaire data on medical history, lifestyle, demography and profession will be collected
|
24 months
|
Description of the standard of care for patients with MN in France
Time Frame: 24 months
|
Treatment names and their duration (in weeks) will be collected
|
24 months
|
the prognostic value of epitope spreading in patients with PLA2R1-associated MN
Time Frame: 24 months
|
Epitope spreading status is determined by measuring the positivity to anti-CysR, anti-CTLD1 and CTLD7 antibodies in the serum, by the means of ELISA and expressed as RU/mL.
The patients with antibodies targetting CysR only are considered as non-spreaders, while the patients additionnaly targetting either CTLD1 and/or CTLD7 are considered as spreaders.
Epitope spreading status (non-spreader or spreader) will be correlated to clinical outcome (complete remission, partial remission or persistent nephrotic syndrome, as defined under primary outcome measures) one year after inclusion.
|
24 months
|
Characterization of HLA typing of MN patients
Time Frame: 12 months
|
Isolation of DNA and genotyping will be performed with the use of standard procedures of Next Generation Sequencing
|
12 months
|
Prognostic value of tissue staining for glomerular deposit of PLA2R1, THSD7A, as welle as of different IgG subclasses
Time Frame: 12 months
|
Positivity for PLA2R1, THSD7A and NELL-1 antigens will be determined using immunostaining with antibodies against PLA2R1, THSD7A and NELL-1, and Positivity for IgG1 IgG2, IgG3 and IgG4 subclasses will be determined using immunostaining with antibodies against IgG1 IgG2, IgG3 and IgG4, respectively, in glomeruli of kidney biopsy at inclusion.
The positivity of tissue staining for PLA2R1, THSD7A and NELL-1or Ig subclasses will be correlated to the patient's clinical outcome one year after inclusion (complete remission, partial remission or persistent nephrotic syndrome, as defined under primary outcome measures).
|
12 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-GIRCI-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Membranous Nephropathy
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... and other collaboratorsCompletedMEMBRANOUS NEPHROPATHYSpain
-
Beijing Friendship HospitalRecruitingIdiopathic Membranous NephropathyChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Peking Union Medical College HospitalBeijing Tongren Hospital; Shanghai Fosun Pharmaceutical Industrial Development... and other collaboratorsRecruitingIdiopathic Membranous NephropathyChina
-
wanglinCompletedIdiopathic Membranous NephropathyChina
-
Manchester University NHS Foundation TrustFresenius AGCompletedAutoimmune Membranous NephropathyUnited Kingdom
-
Guangdong Provincial People's HospitalTerminatedIdiopathic Membranous NephropathyChina
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownIdiopathic Membranous NephropathyChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
Clinical Trials on Blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance